Novavax (NVAX +2.8%) gains after an article published in the Journal of Virology says results...

|By:, SA News Editor

Novavax (NVAX +2.8%) gains after an article published in the Journal of Virology says results from a Phase I/II clinical study of the company's H5N1 influenza vaccine candidate conducted in 2008 were largely successful.